J2S-MC-GZMS
Research type
Research Study
Full title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D
IRAS ID
1013681
Contact name
Tetiana Rudenok
Contact email
Sponsor organisation
Eli Lilly and Company
Research summary
This study is being carried out to find out whether a medicine called brenipatide is safe and effective for people with irritable bowel syndrome with diarrhoea (IBS D). The study will compare different doses of brenipatide with a placebo, which is a dummy treatment containing no active medicine.
Participants may take part in the study for up to approximately 35 weeks. This includes a screening period of up to 3 weeks, a 24 week treatment period, and a safety follow up period of around 8 weeks after the last dose or if treatment is stopped early.
The results of this study will help researchers understand whether brenipatide could be a future treatment option for people with IBS D.REC name
North West - Liverpool Central Research Ethics Committee
REC reference
26/NW/0091
Date of REC Opinion
30 Apr 2026
REC opinion
Further Information Favourable Opinion